OBJECTIVE: To determine the clinical course and outcomes of infants with chronic lung disease (CLD) and pulmonary hypertension (PH) who received prolonged sildenafil therapy. STUDY DESIGN: We conducted a retrospective review of 25 patients <2 years of age with CLD in whom sildenafil was initiated for the treatment of PH while they were hospitalized from January 2004 to October 2007. Hemodynamic improvement was defined by a 20% decrease in the ratio of pulmonary to systemic systolic arterial pressure or improvement in the degree of ventricular septal flattening with serial echocardiograms. RESULTS: Chronic sildenafil therapy (dose range, 1.5-8.0 mg/kg/d) was initiated at a median of 171 days of age (range, 14-673 days of age) for a median duration of 241 days (range, 28-950 days). Twenty-two patients (88%) achieved hemodynamic improvement after a median treatment duration of 40 days (range, 6-600 days). Eleven of the 13 patients with interval estimates of systolic pulmonary artery pressure with echocardiogram showed clinically significant reductions in PH. Five patients (20%) died during the follow-up period. Adverse events leading to cessation or interruption of therapy occurred in 2 patients, 1 for recurrent erections, and the other had the medication held briefly because of intestinal pneumatosis. CONCLUSION: These data suggest that chronic sildenafil therapy is well-tolerated, safe, and effective for infants with PH and CLD.
OBJECTIVE: To determine the clinical course and outcomes of infants with chronic lung disease (CLD) and pulmonary hypertension (PH) who received prolonged sildenafil therapy. STUDY DESIGN: We conducted a retrospective review of 25 patients <2 years of age with CLD in whom sildenafil was initiated for the treatment of PH while they were hospitalized from January 2004 to October 2007. Hemodynamic improvement was defined by a 20% decrease in the ratio of pulmonary to systemic systolic arterial pressure or improvement in the degree of ventricular septal flattening with serial echocardiograms. RESULTS: Chronic sildenafil therapy (dose range, 1.5-8.0 mg/kg/d) was initiated at a median of 171 days of age (range, 14-673 days of age) for a median duration of 241 days (range, 28-950 days). Twenty-two patients (88%) achieved hemodynamic improvement after a median treatment duration of 40 days (range, 6-600 days). Eleven of the 13 patients with interval estimates of systolic pulmonary artery pressure with echocardiogram showed clinically significant reductions in PH. Five patients (20%) died during the follow-up period. Adverse events leading to cessation or interruption of therapy occurred in 2 patients, 1 for recurrent erections, and the other had the medication held briefly because of intestinal pneumatosis. CONCLUSION: These data suggest that chronic sildenafil therapy is well-tolerated, safe, and effective for infants with PH and CLD.
Authors: Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau Journal: N Engl J Med Date: 2002-03-21 Impact factor: 91.245
Authors: Hossein A Ghofrani; Ralph T Schermuly; Frank Rose; Ralph Wiedemann; Markus G Kohstall; André Kreckel; Horst Olschewski; Norbert Weissmann; Beate Enke; Stefanie Ghofrani; Werner Seeger; Friedrich Grimminger Journal: Am J Respir Crit Care Med Date: 2003-01-24 Impact factor: 21.405
Authors: R H Clark; T J Kueser; M W Walker; W M Southgate; J L Huckaby; J A Perez; B J Roy; M Keszler; J P Kinsella Journal: N Engl J Med Date: 2000-02-17 Impact factor: 91.245
Authors: Hossein Ardeschir Ghofrani; Ralph Wiedemann; Frank Rose; Horst Olschewski; Ralph Theo Schermuly; Norbert Weissmann; Werner Seeger; Friedrich Grimminger Journal: Ann Intern Med Date: 2002-04-02 Impact factor: 25.391
Authors: D Dunbar Ivy; Donna Parker; Aimee Doran; Donna Parker; John P Kinsella; Steven H Abman Journal: Am J Cardiol Date: 2003-10-01 Impact factor: 2.778
Authors: Hossein A Ghofrani; Frank Rose; Ralph T Schermuly; Horst Olschewski; Ralph Wiedemann; André Kreckel; Norbert Weissmann; Stefanie Ghofrani; Beate Enke; Werner Seeger; Friedrich Grimminger Journal: J Am Coll Cardiol Date: 2003-07-02 Impact factor: 24.094
Authors: Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245
Authors: Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow Journal: Pediatr Pulmonol Date: 2012-07-06
Authors: Jennifer L Cohen; Shannon N Nees; Gerson A Valencia; Erika B Rosenzweig; Usha S Krishnan Journal: J Pediatr Date: 2018-11-02 Impact factor: 4.406
Authors: Eveline H Shue; Samuel C Schecter; Wenhui Gong; Mozziyar Etemadi; Michael Johengen; Corey Iqbal; S Christopher Derderian; Peter Oishi; Jeffrey R Fineman; Doug Miniati Journal: J Pediatr Surg Date: 2013-10-05 Impact factor: 2.545